EuroScan New technologies News

The International Information Network on New, Emerging and Obsolete Health Technologies (EuroScan International Network e.V.) is a collaborative network of agencies and scientific association of individuals and institutions for the sharing of information and development of methods for the early identification and awareness of key new, emerging or obsolete health-related technologies.


Sulfatinib

A.  Drug Characteristics: Licensee: Huichison MediPharma Indication: Advanced pancreatic neuroendocrine tumors Mechanism of action:Fibroblast growth factor receptor antagonists; Macrophage colony stimulating factor receptor antagonists; Vascular endothelial growth factor receptor antagonists B. Licensing Information Proposed marketing QTR (specify country or world area): FDA Fast track designation (YES/NO): NO   C. Clinical […]


Napabucasin

Overview A.  Drug Characteristics: Licensee: Boston Biomedical Indication: Metastatic Pancreatic Ductal Adenocarcinoma in combination with nab-paclitaxel and gemcitabine Mechanism of action:Beta catenin inhibitors; Cell death stimulants; STAT3 transcription factor inhibitors; Stem cell inhibitors   B. Licensing Information Proposed marketing QTR (specify country or world area): FDA Fast track designation (YES/NO): […]


Glufosfamide

Overview A.  Drug Characteristics: Licensee: Eleison Pharmaceuticals Indication: Metastatic Pancreatic Adenocarcinoma Mechanism of action: Alkylating agents; DNA synthesis inhibitors   B. Licensing Information Proposed marketing QTR (specify country or world area): FDA Fast track designation (YES/NO): NO   C. Clinical evidence Ongoing trials (https://clinicaltrials.gov)   Phase NCT Code Estimated primary […]


Micelplatin (NC-6004)

Overview A.  Drug Characteristics: Licensee: Nanocarrier and Orient Europharma Indication: Treatment of locally advanced or metastatic pancreatic cancer in combination with Gemcitabine Mechanism of action: DNA cross linking agents; DNA synthesis inhibitors   B. Licensing Information Proposed marketing QTR (specify country or world area): FDA Fast track designation (YES/NO): NO […]


PEG ilodecakin

Overview A.  Drug Characteristics: Licensee: Armo Biosciences Indication: Second line treatment of metastatic Pancreatic Cancer Mechanism of action: Interleukin-10 replacements   B. Licensing Information Proposed marketing QTR (specify country or world area): FDA Fast track designation (YES/NO): NO   C. Clinical evidence Ongoing trials (https://clinicaltrials.gov)   Phase NCT Code Estimated […]


Tofacitinib

Overview A.   Drug Characteristics Licensee: Pfizer Indication: treatment of patients with Ulcerative Colitis Mechanism of action: Janus kinases 1.2,3 inhibitor   B.   Licensing Information Proposed marketing QTR (specify country or world area): FDA Fast track designation (YES/NO): NO   C.   Clinical evidence Ongoing trials (https://clinicaltrials.gov) Phase NCT Code Estimated primary […]


SHP 647

Overview A.   Drug Characteristics Licensee: Pfizer Indication: treatment of patients with moderate to severe a Ulcerative Colitis Mechanism of action: Alpha4-beta7 integrin antagonists   B.   Licensing Information Proposed marketing QTR (specify country or world area): FDA Fast track designation (YES/NO): NO   C.   Clinical evidence Ongoing trials (https://clinicaltrials.gov) Phase NCT […]


Risankizumab

Overview A.   Drug Characteristics Licensee: Boehringer Ingelheim Indication: treatment of patients with moderate to severe active Crohn’s disease Mechanism of action: Interleukin-23 subunit p19 inhibitors   B.   Licensing Information Proposed marketing QTR (specify country or world area): FDA Fast track designation (YES/NO): NO   C.   Clinical evidence Ongoing trials (https://clinicaltrials.gov) […]


Ozanimod

Overview A.   Drug Characteristics Licensee: Celgene Indication: treatment of patients with moderate to severe Ulcerative Colitis Mechanism of action: Sphingosine 1 phosphate receptor modulators   B.   Licensing Information Proposed marketing QTR (specify country or world area): FDA Fast track designation (YES/NO): NO   C.   Clinical evidence Ongoing trials (https://clinicaltrials.gov) Phase […]


Filgotinib

Overview A.   Drug Characteristics Licensee: Gilead Sciences Indication: treatment of patients with moderately to severely active Crohn’s disease Mechanism of action: Janus kinase 1 inhibitors   B.   Licensing Information Proposed marketing QTR (specify country or world area): FDA Fast track designation (YES/NO): NO   C.   Clinical evidence Ongoing trials (https://clinicaltrials.gov) […]


Abrilumab

Overview A.   Drug Characteristics Licensee: Amgen Indication: treatment of patients with moderately to severely active Crohn’s Disease Mechanism of action: Alpha4-beta7 integrin antagonists   B.   Licensing Information Proposed marketing QTR (specify country or world area): FDA Fast track designation (YES/NO): NO   C.   Clinical evidence Ongoing trials (https://clinicaltrials.gov) Phase NCT […]


PROCHYMAL® adult human mesenchymal stem cells

Overview A.   Product Characteristics Licensee: Osiris Therapeutics Indication: treatment of patients with moderately to severely active Crohn’s Disease Mechanism of action: Cell replacements; Tissue replacements   B.   Licensing Information Proposed marketing QTR (specify country or world area): FDA Fast track designation (YES/NO): NO   C.   Clinical evidence Ongoing trials (https://clinicaltrials.gov) […]


Upadacitinib

Overview A.   Drug Characteristics Licensee: Abbvie Indication: treatment of patients with moderately to severely active Crohn’s Disease Mechanism of action: Janus kinase 1 inhibitors   B.   Licensing Information Proposed marketing QTR (specify country or world area): FDA Fast track designation (YES/NO): NO   C.   Clinical evidence Ongoing trials (https://clinicaltrials.gov) Phase […]


Injectable extended-release naltrexone to treat opioid use disorder

Vivitrol is an extended-release injectable formulation of naltrexone, administered as an intramuscular injection once a month. Naltrexone is an opioid-receptor antagonist that blocks the euphoric effects of opioids. Unlike other treatments for opioid use disorder, including buprenorphine/naloxone and methadone, naltrexone is not associated with the development of tolerance and dependence, […]